-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic kidney disease (CKD) and type 2 diabetes (T2D) are independently related to heart failure (HF), which is the main cause of morbidity and mortality in patients
.
In the FIDELIO-DKD and FIGARODKD trials, Finerenone (a selective non-steroidal mineralocorticoid receptor antagonist) improved cardiovascular outcomes in patients with albuminuria CKD and T2D
Recently, a research article was published in Circulation, an authoritative journal in the cardiovascular field.
These preset analyses from FIGARO-DKD evaluated the impact of Finerenone on clinically important HF outcomes
.
Patients with T2D and albuminuria CKD (urinary albumin-creatinine ratio [UACR]≥30 to <300mg/g, and estimated glomerular filtration rate [eGFR]≥25 to ≤90ml/min/1.
Outcomes of first event include: new HF (patients with no history of HF at baseline were hospitalized for HF for the first time [HHF]); cardiovascular death or first HHF; HF-related death or first HHF; first HHF; cardiovascular death or all (first or Relapse) HHF; HF-related death or total HHF; and total HHF
.
Outcomes were assessed in the overall population and pre-designated subgroups classified by baseline HF history
A total of 7352 patients were included in the analysis; 571 (7.
8%) patients had a history of HF at baseline
.
Compared with placebo, Finerenone significantly reduced new-onset HF (1.
It can be seen that the results of these FIGARO-DKD analyses show that, regardless of whether it is accompanied by a history of HF, Finerenone can reduce new HF in CKD and T2D patients and improve other HF outcomes
.
.
Original source:
Original source:Gerasimos Filippatos, et al.
Leave a message here
